Biopolymer-Capped Pyrazinamide-Loaded Colloidosomes: In Vitro Characterization and Bioavailability Studies

Area of Science:

• Materials Science
• Pharmaceutical Sciences
• Nanotechnology

Background:

• Pyrazinamide (PZA) is a crucial drug for tuberculosis treatment.
• Developing effective drug delivery systems is essential to improve PZA bioavailability and efficacy.
• Colloidosomes offer a promising platform for encapsulating and delivering therapeutic agents.

Purpose of the Study:

• To prepare and characterize pyrazinamide (PZA)-loaded colloidosomes.
• To optimize the formulation of PZA-loaded colloidosomes using a central composite design.
• To evaluate the drug loading, release profile, and pharmacokinetic performance of the PZA-loaded colloidosomes.

Main Methods:

• Colloidosome particles were prepared using an in situ gelation technique with calcium carbonate (CaCO3) shells.
• A central composite design was employed to optimize CaCO3, sodium alginate, and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) concentrations.
• Particle characterization involved field emission scanning electron microscopy (FESEM), FTIR, DSC, TGA-DTA, and XRD analyses.
• Pharmacokinetic studies were conducted to compare PZA-loaded colloidosomes with PZA solution.

Main Results:

• Optimal formulation yielded maximum drug loading and an efficient release profile.
• FESEM confirmed spherical, porous particles with effective PHBV polymer coating.
• Spectroscopic and thermal analyses indicated good compatibility between PZA and excipients.
• Pharmacokinetic studies showed a 4.26-fold increase in plasma drug concentration (AUC0-∞) and higher Cmax for PZA-loaded colloidosomes compared to PZA solution.

Conclusions:

• The prepared PZA-loaded colloidosomes demonstrate excellent potential as effective drug carriers.
• The optimized formulation ensures efficient drug loading and controlled release.
• Colloidosome technology offers a viable strategy for enhancing PZA delivery and therapeutic outcomes.